Abstract
Two hundred twenty eligible patients with metastatic colorectal carcinoma were treated with a combination of beta-2'-deoxythioguanosine (BTG), plus methyl-CCNU or mitomycin. There was no significant difference in overall response (CR/PR + stable) among fully evaluable patients between the mitomycin plus BTG arm 19/96 (19.7%) and the MeCCNU arm 26/87 (29.8%). Median survival of eligible patients was 19 weeks with mitomycin plus BTG versus 21 weeks with MeCCNU plus BTG: no difference. Median survival of responders (40 weeks) and patients with stable disease (35 weeks) was significantly better than patients with increasing disease (17 weeks): p + 0.001.
Publication types
-
Comparative Study
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Adenocarcinoma / mortality
-
Colonic Neoplasms / drug therapy*
-
Colonic Neoplasms / mortality
-
Deoxyguanosine / administration & dosage
-
Deoxyguanosine / adverse effects
-
Deoxyguanosine / analogs & derivatives*
-
Deoxyguanosine / therapeutic use
-
Drug Evaluation
-
Drug Therapy, Combination
-
Humans
-
Leukopenia / chemically induced
-
Lomustine / administration & dosage*
-
Lomustine / adverse effects
-
Lomustine / analogs & derivatives
-
Lomustine / therapeutic use
-
Mitomycins / administration & dosage*
-
Mitomycins / adverse effects
-
Mitomycins / therapeutic use
-
Nausea / chemically induced
-
Nitrosourea Compounds / administration & dosage*
-
Thionucleosides / administration & dosage*
-
Thionucleosides / adverse effects
-
Thionucleosides / therapeutic use
-
Thrombocytopenia / chemically induced
Substances
-
Mitomycins
-
Nitrosourea Compounds
-
Thionucleosides
-
beta-2'-deoxythioguanosine
-
Lomustine
-
Deoxyguanosine